Half of U.S. invasive cancers still meet the radiation beam
Radiation therapy aims ionizing beams—usually from a linear accelerator—to damage tumor DNA while sparing neighbors. About half of America’s 1.2 million invasive cancers diagnosed in 2022 included radiotherapy. It can cure localized disease, backstop surgery, partner with chemotherapy, or ease symptoms when cure is gone.
Shaped beams from many angles intersect at the tumor so absorbed dose peaks there; fields may cover at-risk lymph nodes and a margin for breathing, bladder fill, and setup drift. Radiation oncology prescribes treatment; radiology images. Intent may be curative, adjuvant, neoadjuvant, or palliative. Total body irradiation readies bone-marrow transplants; brachytherapy plants sources beside breast, prostate, and other targets. Non-cancer uses—trigeminal neuralgia, keloid prevention, and more—stay limited by second-cancer risk.
Radiosensitivity varies: leukemias, many lymphomas, and germ-cell tumors die at modest doses; most epithelial cancers need about 60–70 Gy for radical cure; renal cell carcinoma and melanoma resist yet may still get palliation. Laboratory sensitivity is not clinical curability—disseminated leukemia outruns local beams, while early lymphomas or prostate cancers can be cured. Large masses respond worse than microscopic disease, so surgeons debulk, chemo shrinks, or drugs such as cisplatin sensitize. After breast-conserving surgery, radiotherapy halves recurrence rates.
CT planning, skin marks, molds, and image guidance lock daily position; MR-guided adaptive plans reshape high-dose clouds as anatomy shifts. The treatment itself is painless, but roughly five percent of cases see serious complications. Acute injury may follow about 50 Gy; late injury after about 65 Gy can appear months to decades later. Fatigue and sunburn-like skin dominate; abdominal fields bring nausea; head-and-neck courses ulcerate mucosa. In pancreatic cancer, radiotherapy has lengthened survival for inoperable tumors. Modern practice shrinks collateral harm while keeping the beam’s bargain: controlled damage as medicine.
Source: Radiation therapy
